A spin-out from the Department of Pharmacology at the University of Cambridge, PolyProx is based on over a decade of research and intellectual property from founder Professor Laura Itzhaki’s laboratory.
PolyProx will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.
Polyproxin™ molecules target disease-causing proteins within tumour cells and trigger pathways to eliminate these proteins, thereby halting further growth of the tumour.
This approach has the potential to address cancer targets that have proven untreatable using current technologies, important in major diseases such as lung, colorectal and pancreatic cancers.
The company raised £3.4 million seed capital in April 2019. The financing, which was co-led by Cambridge Innovation Capital plc (CIC), RT Capital and Cambridge Enterprise, will support research operations to validate the technology across a range of tumour targets over the next two years.
Professor Itzhaki is joined at PolyProx by serial Cambridge biotech entrepreneurs Kevin Moulder as chief operating officer and Andrew Sandham as executive chairman.